Veronika Schwarzová
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Veronika Schwarzová has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Marcela Kreslová
Department of Paediatrics, University Hospital, Faculty of Medicine in Pilsen, Charles University
3 shared publications Hana Hrdinová
Department of Imaging Methods, 2nd Faculty of Medicine Charles University and Motol University Hospital Prague Czech Republic
2 shared publicationsJan Baxa
Department of Imaging Methods University Hospital, Faculty of Medicine in Pilsen, Charles University in Prague Prague Czech Republic
2 shared publications- Jana Amlerová
Department of Neurology, Second Faculty of Medicine Charles University Prague Czech Republic
2 shared publications Josef Sýkora
Department of Paediatrics University Hospital, Faculty of Medicine in Pilsen, Charles University in Prague Prague Czech Republic
2 shared publicationsRomana Kaslová
Department of Paediatrics University Hospital, Faculty of Medicine in Pilsen, Charles University in Prague Prague Czech Republic
2 shared publications
Latest Publications
- 15 July 2025
- Published by Wiley in Pediatric Pulmonology
- Vol. 60 (7) , e71208
Elexacaftor/Tezacaftor/Ivacaftor for Mycobacterium abscessus Eradication in a Child With Cystic Fibrosis
- 15 July 2025
- Published by Wiley in Pediatric Pulmonology
- Vol. 60 (7) , e71208
Elexacaftor/Tezacaftor/Ivacaftor for Mycobacterium abscessus Eradication in a Child With Cystic Fibrosis
- Open Access
- 18 November 2024
- Published by Wiley
Elexacaftor/Tezacaftor/Ivacaftor for Mycobacterium abs. Eradication in a Child with Cystic Fibrosis
- 18 November 2024
- Published by Wiley
Open AccessElexacaftor/Tezacaftor/Ivacaftor for Mycobacterium abs. Eradication in a Child with Cystic Fibrosis
- 20 December 2022
- Published by Wiley in Pediatric Pulmonology
- Vol. 58 (3) , 980-982
Pulmonary tularaemia in a female adolescent with inflammatory bowel disease receiving infliximab: Do not miss the diagnosis
We report the first described case of pulmonary tularaemia in the pediatric patient receiving infliximab for ulcerative colitis. We highlight the importance of considering Francisella tularensis in diagnostically challenging cases of persistent respiratory symptoms to facilitate early diagnosis and adequate therapy. The TCR‐γδ + DN T cells are gaining important role in clinical practice. Polymerase chain reaction assays and serology guarantee early recognition.
- 20 December 2022
- Published by Wiley in Pediatric Pulmonology
- Vol. 58 (3) , 980-982
Pulmonary tularaemia in a female adolescent with inflammatory bowel disease receiving infliximab: Do not miss the diagnosis
We report the first described case of pulmonary tularaemia in the pediatric patient receiving infliximab for ulcerative colitis. We highlight the importance of considering Francisella tularensis in diagnostically challenging cases of persistent respiratory symptoms to facilitate early diagnosis and adequate therapy. The TCR‐γδ + DN T cells are gaining important role in clinical practice. Polymerase chain reaction assays and serology guarantee early recognition.